权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Specific Detection of Antibodies to Emerging and Established Arboviruses Including Zika Virus

针对新出现和已建立的虫媒病毒（包括寨卡病毒）的抗体的特异性检测

基本信息

批准号：
9347926
负责人：
DAVID CAMERINI
金额：
$ 22.5万
依托单位：
IMMPORT THERAPEUTICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-02-06 至 2019-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9347926
关键词：
Adult Algorithms Americas Antibodies Arboviruses Area Biological Assay Burkholderia pseudomallei Chikungunya virus Clinical Country Cross Reactions Culicidae Dengue Virus Detection Development Diagnostic Disease Emergency Situation Epidemic Epitopes Florida Future Genome Geographic state Goals Guillain-Barré Syndrome Hawaii Health Incidence Indigenous Individual Infection International Melioidosis Methods Mexico Microcephaly Neurologic Neutralization Tests Pathogenicity Pattern Phase Protein Fragment Protein Microchips Proteins Proteome Proteomics Public Health Puerto Rico Reporting Saliva Serotyping Serum Specificity Technology Testing Universities Vaccines Validation Viral Proteins Virus Virus Diseases Washington West Nile viral infection West Nile virus Work World Health Organization Yellow fever virus Zika Virus base combat cross reactivity in utero innovation member novel strategies point of care public health emergency response sample collection seropositive specific biomarkers therapeutic development therapeutic vaccine tool transmission process

项目摘要

Abstract Zika virus (ZIKV) infection is currently an epidemic in the western hemisphere. It is a WHO-declared “Public Health Emergency of International Concern” since February 2016 due to the association of ZIKV infection with microcephaly and other neurologic abnormalities in babies infected in utero and with Guillain-Barre syndrome in infected adults. An estimated four million ZIKV infections have occurred in the Americas in 2016 and over two billion people live in areas conducive to mosquito-borne transmission of ZIKV worldwide. To date, autochthonous ZIKV infection has been reported in over 40 countries in the western hemisphere including the US protectorate, Puerto Rico, and state of Florida. There is a clear need for accurate and practical methods of detecting ZIKV infection as well as for the development of therapeutic agents and vaccines to combat the associated disease. Detection of ZIKV infection is hampered, however, by the cross-reactivity of anti-ZIKV antibodies with other arboviruses present in the same areas including DENV and CHIKV and visa-versa. Specifically, neutralization- based serodiagnostic tests (notably plaque-reduction neutralization tests, PRNT) cannot cleanly distinguish between seropositivity to different members of this set of arboviruses, perhaps because antibodies directed at neutralizing epitopes tend to be cross-reactive. In this application we propose an innovative and comprehensive method for discovering targets of non-cross-reactive antibodies to emerging and established arboviruses and propose to begin with ZIKV due to the international public health emergency created by this virus.

文摘